Ikarian Capital’s Praxis Precision Medicines PRAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.02M Sell
6,942
-65,900
-90% -$21.8M 0.2% 104
2026
Q2
$24.4M Buy
72,842
+1,261
+2% +$399K 2.63% 9
2026
Q1
$23.1M Sell
71,581
-15,000
-17% -$4.64M 1.87% 13
2025
Q4
$25.5M Buy
86,581
+58,010
+203% +$10.8M 1.99% 10
2025
Q3
$1.51M Sell
28,571
-248,379
-90% -$12M 0.15% 107
2025
Q2
$11.6M Buy
276,950
+131,448
+90% +$5.01M 2.24% 13
2025
Q1
$5.51M Buy
+145,502
New +$9.09M 0.68% 32
2024
Q2
– Sell
-168,388
Closed -$7.96M – 147
2024
Q1
$10.3M Sell
168,388
-31,612
-16% -$1.42M 1.13% 27
2023
Q4
$4.46M Buy
200,000
+50,000
+33% +$901K 0.42% 63
2023
Q3
$3.85M Buy
+150,000
New +$2.84M 0.46% 57
2023
Q1
– Sell
-10,000
Closed -$357K – 130
2022
Q4
$357K Buy
+10,000
New +$312K 0.09% 65
2021
Q1
– Sell
-333
Closed -$275K – 324
2020
Q4
$275K Buy
+333
New +$194K 0.01% 208

Other funds holding PRAX

Ikarian Capital's PRAX Position: Q3 2026 in Review

Ikarian Capital reduced its Praxis Precision Medicines (PRAX) stake by 90% in Q3 2026, selling an estimated $21.8M and leaving 6,942 shares worth $2.02M. The position accounts for 0.2% of the portfolio, ranked #104.

Ikarian Capital first reported a position in PRAX in Q4 2020 and has held it in 12 quarters since. The position peaked at $25.5M in Q4 2025. 339 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

  • Ikarian Capital held 6,942 shares of Praxis Precision Medicines worth $2.02M as of Q3 2026.
  • Ikarian Capital sold 65,900 Praxis Precision Medicines shares in Q3 2026, an estimated $21.8M.
  • Praxis Precision Medicines made up 0.2% of Ikarian Capital's portfolio in Q3 2026, its #104 holding.
  • Ikarian Capital first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 12 quarters since.
  • Ikarian Capital's Praxis Precision Medicines position peaked at $25.5M in Q4 2025.
  • 339 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on Ikarian Capital's 13F filing for Q3 2026, filed 16 Nov 2026.